Darius M. Moshfeghi MD, FASRS

Dr. Darius M. Moshfeghi is Chief of the Retina Division and Professor at the Horngren Family Vitreoretinal Center, Byers Eye Institute, Department of Ophthalmology, at the Stanford University School of Medicine. Dr. Moshfeghi received training in biomedical engineering as an undergraduate at Tulane University in New Orleans, followed by medical school, internship, and ophthalmology residency also at Tulane. Subsequently, he performed fellowships in ocular oncology and orbital disease, followed by a 2-year vitreoretinal surgery fellowship at the Cole Eye Institute of the Cleveland Clinic Foundation. He was introduced to the concept of wide-angle imaging and its potential for telemedicine in pediatric retinal disease while treating patients with retinoblastoma at St. Jude Children's Research Hospital in Memphis, Tennessee. He is an internationally-recognized expert in pediatric vitreoretinal disease and pediatric retinal telemedicine. He has dedicated his career to using telemedicine and digital technology to prevent blindness in children.

He founded the Stanford University Network for Diagnosis of Retinopathy of Prematurity (SUNDROP) program in 2005, and today it remains the oldest and largest telemedicine screening program for ROP in the United States. He has developed a national telemedicine screening program for Pediatrix with Stanford University for ROP called TELEROP. He has worked with the industry both in a consultative and creative-founder role to develop wide-angle imaging camera technology as well as deep learning classifier platforms for the identification of disease in healthy-term newborn infants.

He is actively involved in entrepreneurial activities, serving as a founder and a director of Pr3vent, Placid0, dSentz, and Promisight. He is actively engaged in promoting telemedicine to expand access to eye care and vision for all. He currently serves on the American Academy of Ophthalmology (AAO) Telemedicine Working Group and previously sat on the AAO's ROP Telemedicine Task Force Panel. Additionally, he is a founding member of the Collaborative Community on Ophthalmic Imaging a collaboration between stakeholders and the FDA which was established by Mark Blumenkranz here at Stanford University.

He has collaborated extensively with the pharmaceutical industry in oversight (Alcon and Novartis Data Safety Monitoring Committees for Brolucizumab, Novartis Safety Review Committee Brolucizumab), steering committees (Regeneron Butterfleye, Bayer Photographic Committee for Firefleye, Iconic Therapeutics, Pykus), and drug development (Alexion).

Finally, Dr. Moshfeghi is interested in medical training and mentoring individuals pursuing careers in medicine and biomedical spaces. He was the founding director of the Stanford Vitreoretinal Surgery and Medical Disease Fellowship and remains actively engaged in the day-to-day training of the fellows and works extensively with medical students (and has served as a MedScholars mentor for many students) and visiting fellows.